We are proud to announce the release of new scientific publication at the Journal of Cancer Research and Clinical Oncology on Protectival’s (clinical name: LCS101)  synergistic effect with radiotherapy.

From the publication:

The addition of the botanical formula LCS101 to irradiated cancer cells results in an apparent additive effect, most likely through a ROS-mediated mechanism. These findings support the use of LCS101 by patients undergoing radiation therapy, for both its clinical as well as anti-cancer effects.

Click here for the full publication. 

More from our Blog

The Emergence of Integrative Oncology

The Emergence of Integrative Oncology

How Integrative Oncology is setting a standard for modern medicine   Patients with cancer are turning to integrative oncology as part of their cancer and survivorship care. Studies from around the world are more frequently reporting the increased use of...

read more
Protectival’s effect on quality of life

Protectival’s effect on quality of life

Quality of life is a big consideration when making health care decisions. Doctors have managing disease foremost on their minds. Patients should have managing their health foremost on theirs. When going through intense treatment regimens, quality of life can sometimes suffer. Protectival is here to help patients maintain the highest quality of life, which gives them the best fighting chance.

read more
Protectival’s Multi Layered Safety

Protectival’s Multi Layered Safety

Safety is LifeBiotic’s main concern. We understand that people considering Protectival are in many cases facing some of the most challenging health decisions of their lives.  As such we structured unique control and safety processes to ensure Protectival’s quality and...

read more
JoinLifeBiotic's Newsletter

JoinLifeBiotic's Newsletter

 

Receive the latest news, updates and offers from our team.

You have Successfully Subscribed!

Share This
0